论文部分内容阅读
目的探讨单纯应用丽珠胃三联(克拉霉素+替硝唑+枸椽酸铋钾)根除幽门螺旋杆菌(helicobacter pylori,Hp)对原发性胃黏膜相关性组织淋巴瘤(MALT)的治疗效果。方法对胃镜检查发现的17例原发性胃MALT及12例淋巴细胞性胃炎患者给予丽珠胃三联单纯抗Hp治疗,观察患者治疗反应、预后及缓解情况。结果所有患者Hp感染率为82.8%(24/29)。原发性胃MALT患者无特异性临床表现,早期诊断率较低;Hp感染与原发性胃MALT相关。29例患者接受丽珠胃三联抗Hp治疗后,19例患者获得完全缓解,10例患者症状及肿瘤的大小均有不同程度的改善,有效率100%(29/29)。结论原发性胃MALT与Hp感染相关,单纯应用丽珠胃三联抗Hp可以治疗原发性胃MALT,并可改善患者预后。
Objective To investigate the therapeutic effect of helicobacter pylori (Hp) alone on gastric mucosa-associated tissue lymphoma (MALT) treated with Livzon triple therapy (clarithromycin + tinidazole + bismuth potassium citrate) . Methods 17 cases of primary gastric MALT and 12 cases of lymphocytic gastritis found by gastroscopy were treated with Livzon stomach triple anti-Hp therapy. The response, prognosis and remission were observed. Results The Hp infection rate was 82.8% (24/29) in all patients. Primary gastric MALT patients have no specific clinical manifestations, early diagnosis rate is low; Hp infection is associated with primary gastric MALT. Nineteen patients achieved complete remission after treatment with Livzon stomach triple anti-Hp therapy. The symptoms and tumor size of 10 patients improved to some extent with an effective rate of 100% (29/29). Conclusions The primary gastric MALT is associated with Hp infection. Using Livzon stomach triple anti-Hp can treat primary gastric MALT and improve the prognosis.